<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066650</url>
  </required_header>
  <id_info>
    <org_study_id>TWENTE I</org_study_id>
    <secondary_id>MST/Twente/001</secondary_id>
    <nct_id>NCT01066650</nct_id>
  </id_info>
  <brief_title>The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente</brief_title>
  <acronym>TWENTE</acronym>
  <official_title>The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardio Research Enschede BV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardio Research Enschede BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TWENTE Study is a single center prospective single-blinded randomized study.
      Randomization will involve the type of Drug-Eluting Stent (DES) used in study population.
      Patients will be blinded to the type of DES they will receive. The general practitioner of
      the patient will be requested not to disclose this information to the patient. Analysts who
      perform the data analyses will be blinded to the type DES used as well.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary research questions

      To investigate whether the clinical outcome following the randomized implantation of the
      Endeavor Resolute® versus XIENCE V® drug-eluting stent is similar, as assessed in a
      non-inferiority setting by comparing target-vessel failure (TVF) of both stents. We want to
      compare for both drug-eluting stents the combined endpoint of death, myocardial infarction or
      revascularization related to the target-vessel, as well as death or myocardial infarction
      that cannot be related to a significant flow obstruction in another vessel or to another
      cause. According to current literature, non-inferiority of Endeavor resolute ® and XIENCE V®
      is expected. But the non-inferiority of Endeavor resolute and XIENCE V® is not tested in a
      controlled randomized trial yet.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparing target-vessel failure (TVF) of both stents</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the efficacy, safety, clinical short- and long-term outcome, and the acute angiographic results of the implantation of two second-generation drug-eluting stents</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1391</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Unstable Angina Pectoris</condition>
  <condition>Coronary Stenosis</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Endeavor Resolute</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)</intervention_name>
    <description>Drug eluting Stent</description>
    <arm_group_label>Endeavor Resolute</arm_group_label>
    <other_name>Endeavor Resolute stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience V (Everolimus-eluting stent)</intervention_name>
    <description>Drug eluting stent</description>
    <arm_group_label>Xience V</arm_group_label>
    <other_name>Xience V drug eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for PCI with DES implantation based on VVC/ESC guidelines and/or clinical
             decision of interventional cardiologist

          -  Age ≥ 18 years and mentally capable to give an informed consent

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients with ST-elevation myocardial infarction (STEMI) or an ST- elevation
             myocardial infarction equivalent requiring primary PCI or rescue PCI

          -  Patients in whom the revascularization procedure is planned to be performed in a
             staged approach

          -  Renal failure requiring haemodialysis

          -  Patient is currently participating in an investigational drug or device study that has
             been not completed

          -  In the investigators opinion patient has a co-morbid condition(s) that could limit the
             patient's ability to participate in the study, compliance with follow-up requirements
             or impact the scientific integrity of the study

          -  Life expectancy less than 1 year

          -  Patients in whom during PCI there is no indication for DES use and/or if the operator
             chooses not to use a DES based on the clinical situation, the patient will be
             excluded.

          -  If the choice of DES is dictated by logistic reasons e.g. the required DES dimensions
             is provided by one manufacturer only.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. von Birgelen, MD,PhD,Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thorax Centrum Twente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Spectrum Twnete</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7513ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thorax Centrum Twente</investigator_affiliation>
    <investigator_full_name>prof. C. von Birgelen</investigator_full_name>
    <investigator_title>Professor Clemens von Birgelen</investigator_title>
  </responsible_party>
  <keyword>TWENTE</keyword>
  <keyword>randomized study</keyword>
  <keyword>stent</keyword>
  <keyword>coronary stent</keyword>
  <keyword>drug-eluting stent</keyword>
  <keyword>Zotarolimus</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Xience V</keyword>
  <keyword>Endeavor Resolute</keyword>
  <keyword>head to head comparison</keyword>
  <keyword>real world patients</keyword>
  <keyword>target vessel failure</keyword>
  <keyword>investigator initiated study</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>coronary arteries</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>non inferiority</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

